(23) illustrated that in pancreatic cancer tissues, miR-126 is notably downregulated, while ADAM9 (a disintegrin and metalloprotease 9), the target gene of miR-126, is significantly upregulated. This evidence concerns the gene ADAM9 and pancreatic neoplasm.